Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Rumpl3StiltSkinon Jul 04, 2022 12:26pm
204 Views
Post# 34799386

RE:Safety and Partial Response

RE:Safety and Partial Response
Kingpin68 wrote:
Perhaps others can clarify something. Keytruda states almost 19% had an 'ongoing' response at 12 months. I was trying to find if that was CR only or included PR. TLT has significant PR as well and I wonder if PR patients would be saved from having bladder removal. If so, this is significant data. I also knew from this board that the view was that tld1433 was much safer than keytruda but didn't realize the scope of safety concerns with keytruda. Their site talks about keytruda causing the immune system to attack normal organs and tissue, which can happen even after treatment and possibly lead to death. Not sure how prevalent that issue is, as I couldn't find more specific info. It seems so far that TLT's treatment is far less risky.


Good points King. The thing qith 1433, as you've alluded to at least. PRs are important. Cuz with low adverse reactions, high safety. 1433 can be re-tried. Over and over, turning NRs to PR/CRs, turning PRs to CRs... ;-)

<< Previous
Bullboard Posts
Next >>